EFFICACY OF BAMLANIVIMAB COMPARED TO STANDARD CARE IN TREATMENT OF THE PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Bamlanivimab is a monoclonal antibody for the treatment of mild to moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta-analysis review study was to compare the efficacy of bamlanivimab and standard treatment in the treatment of patients with Covid-19.
PubMed, Scopus, Cochrane Library and Web of Science databases were searched to identify relevant articles from 2020 to 2023. Also, a manual search was performed in the sources of primary review and key studies. There were no restrictions on the language of the studies. Evaluation of the quality of studies was done with the Newcastle tool. Data analysis was done using Review Manager software version 5.4.
In total, 16 studies including 23166 covid-19 patients were included in the study. The results of the meta-analysis showed that a significant difference was observed between the bamlanivimab and standard care groups in terms of mortality rate (odds ratio [OR] = 0.26, confidence interval [CI]: 0.17 to 0.42, P>0.001), hospitalization rate (OR= 0.45; 95% CI: 0.31 to 0.66, P>0.001), and ICU admission (OR= 0.39; 95% CI: 0.21 to 0.72, P=0.003).
According to evidence from the current review, bamlanivimab reduces mortality, risk of hospitalization, and intensive care unit (ICU) admission in the patients with mild or moderate Covid-19. The results of this study can help health policy makers in choosing effective treatments for Covid-19 patients.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.